How being small helps one business react quickly

Being small is helping GlycoForm to manage risk effectively

After a successful career spanning more than 20 years in the pharmaceutical industry, David Scales, 56, decided it was time to change direction. Rather than remain within "big pharma", Scales opted to move into the biotechnology sector in 2000 and work with smaller companies. And in July last year, Scales was appointed chief executive officer at GlycoForm Ltd, a company that specialises in synthesising complex sugars and incorporating them into other molecules, especially proteins. Since a protein's ability to have a drug-like effect is often dependent upon it having the right complex sugars as part of its make-up, GlycoForm's technology has obvious value in drug development.



"GlycoForm is a small company with only 10 scientists," says Scales. "But that team is the best in the world at what it does – and the reason I wanted to lead the business." Since joining, Scales has set about refocusing the company's scientific projects and has raised additional finance – no mean feat in the current funding climate. Although in common with other companies that operate high-tech laboratories, running costs are high. "We don't have the buying power of large companies and so it's difficult to get much of a discount on laboratory consumables," explains Scales.

However, that problem was solved for GlycoForm through its membership of OBN, an Abingdon-based network organisation for bioscience companies (www.obn.org.uk). OBN's purchasing scheme allows member companies to pool their orders and achieve meaningful discounts from suppliers. "We predict that over the year we will save in excess of £10,000," says Scales. "Not much in big pharma terms, but for small companies that can mean the difference between survival and closure. There's no doubt that OBN's purchasing scheme is really important for our business."

Looking to the future, Scales intends to maintain this prudent approach to cash while the company develops its technology. An income stream from licensing that technology to large pharmaceutical companies will then follow. And that revenue will, in turn, be used by GlycoForm to develop its own potential drugs. The future therefore looks exciting for GlycoForm, but what about the risk?

"Job security in large companies is no longer what it was even a few months ago," observes Scales. "As a small business we can react to new opportunities and take decisions quickly. That makes us able to manage risk more effectively than many large businesses." Wise words: in these difficult financial times, small really might be beautiful.

Glycoform Ltd (01235 820463; www.glycoform.co.uk)



Independent Comment
blog comments powered by Disqus
Career Services

Day In a Page

The 50 Best beachwear

The 50 Best beachwear

The hottest summer gear for men and women
Still standing: George Galloway reveals why his staunchly Leftist outlook is still invariably right

Still standing: George Galloway

Written off, ridiculed, wrongly accused of taking bribes the honourable member for Bradford West, has never bowed to the critics.
How will Daniel Radcliffe's fans react to his latest turn - as a damaged, drug-taking Beatnik poet?

Daniel Radcliffe as drug-taking Beatnik poet

His decade as the boy wizard may be over, but that hasn't hexed Daniel Radcliffe's enchanted life.
For whom the bell tolls: £20m 'Memo' project takes shape on Dorset's Jurassic coast

'Memo' project takes shape on Dorset coast

It started as a stonemason's visionary idea – to commemorate all the species that have ever existed and are now extinct.
Just add sunshine: Bill Granger's Turkish delights

Just add sunshine: Bill Granger's Turkish delights

Turkish cuisine is perfect for those long, sociable weekend meals with friends. It's just a shame that money can't buy the key ingredient.
Objets czar: David Usborne’s collection of myriad objects is quite the mystery

Objets czar: David Usborne’s collection of myriad objects

To others, they're junk. To David Usborne, they are his life: useful gizmos, mysterious thingamajigs and anonymous articles that dominate his home.
The iron ore lady: Why the world's richest woman is mired in controversy

World's richest woman: Gina Rinehart

Family feuds, attempts to control the Australian media and bitter public disputes are keeping the mining magnate in the headlines.
We just click: How Lego keeps building on its success

How Lego keeps building on its success

This year, Lego announced record profits. Gerard Gilbert visits its Denmark HQ.
The other bits: Mark Hix creates delicious and economical meals with cheaper cuts of meat

Mark Hix cooks with cheaper cuts of meat

Our chef creates delicious and economical meals on a budget
Strokes of genius: How to create summer's bold make-up look

Strokes of genius: Summer's bold make-up

From coral lips to fly-away fringes, make-up artist Kim Brown and hair stylist Richard Scorer reveal how to create the look
Marking his territory: Kilian Hennessy creates fragrances designed to provoke the senses

Marking his territory: Kilian Hennessy

The perfumer creates fragrances designed to provoke the senses
Photo essay: Britain's 1948 Olympians today

Britain's 1948 Olympians today

Photo essay
The top five E3 2012 triumphs: From Ubisoft's suite of titles to Dishonored and The Last of Us

The top five E3 2012 triumphs

The games and moments that left us grinning like the Cheshire Cat
The green movement at 50: Can the world be saved?

Can the world be saved?

Population growth and climate change are the big problems facing the earth in the next 50 years. But are there any solutions?
France: Will xenophobia go mainstream?

France: Will xenophobia go mainstream?

In the beautiful Rhone delta, John Lichfield visits a village where a dangerous new political landscape is taking shape